PEOPLE - BioTransplant (US) vice-president to leave:
This article was originally published in Clinica
Dr Robert Kaufmann is to leave BioTransplant to pursue other opportunities. He was vice-president of clinical affairs at the US developer of organ transplantation systems.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.